13,592 Shares in Ralliant Corporation $RAL Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Ralliant Corporation (NYSE:RAL) during the 2nd quarter, HoldingsChannel reports. The firm bought 13,592 shares of the company’s stock, valued at approximately $1,001,000.

Other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares in the last quarter. Rothschild Investment LLC boosted its stake in shares of Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after purchasing an additional 303 shares in the last quarter. Keybank National Association OH boosted its stake in shares of Ralliant by 1.6% during the fourth quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock valued at $1,001,000 after purchasing an additional 305 shares in the last quarter. UMB Bank n.a. increased its holdings in Ralliant by 49.6% during the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after buying an additional 326 shares during the period. Finally, Maryland State Retirement & Pension System increased its holdings in Ralliant by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock valued at $1,117,000 after buying an additional 329 shares during the period.

Ralliant Stock Down 0.4%

Shares of Ralliant stock opened at $72.03 on Tuesday. The firm’s 50 day moving average price is $68.82 and its 200-day moving average price is $55.58. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The company has a market cap of $7.97 billion, a P/E ratio of -6.64, a PEG ratio of 2.69 and a beta of 1.61.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million during the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, sell-side analysts predict that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is presently -1.84%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RAL. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. BMO Capital Markets initiated coverage on Ralliant in a research report on Monday, July 20th. They set a “market perform” rating and a $78.00 target price on the stock. Royal Bank Of Canada lifted their price target on Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Truist Financial reissued a “buy” rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. Finally, Wall Street Zen cut Ralliant from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.70.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.